title: Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese.
abstract: BACKGROUND
  Angiotensin-converting enzyme inhibitors have been shown experimentally to prevent restenosis after balloon injury. We previously reported that quinapril reduced the 6-month restenosis (percent diameter stenosis >or=50%) rate after percutaneous coronary intervention (PCI). However, it was not established whether this favorable outcome was maintained for longer periods.
  
  
  METHODS
  This study was a prospective, randomized, open, and non-placebo controlled trial. Patients with coronary artery disease were enrolled after successful coronary balloon angioplasty or stenting. Two hundred and fifty-three patients were randomly assigned to the quinapril (10-20 mg per day) or control groups. The major clinical end points included death, myocardial infarction, cerebrovascular accident, or revascularization (either coronary artery bypass grafting or repeat PCI). These were tabulated according to the intention-to-treat principle.
  
  
  RESULTS
  Long-term follow-up was available with a median of 4.8 (interquartile range 4.2-5.1) years after the procedure. The incidence of combined end points of mortality and morbidity (myocardial infarction and cerebrovascular accident) in the quinapril group was lower than that in the control group (6.1% vs 14.8%; relative risk [RR] 0.42, 95% CI 0.18-0.96, P =.033). The overall incidence of end-point events in patients with quinapril also occurred less frequently (29.8% vs 46.7%; RR 0.58, 95% CI 0.38-0.86, P =.007).
  
  
  CONCLUSIONS
  These clinical outcomes show that the benefit of quinapril in patients following PCI is maintained for 4 years.
authors.affiliation: Department of Molecular and Internal Medicine, Division of Clinical Medical Science, Programs for Applied Biomedicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. Masaya.Otsuka@ma7.seikyou.ne.jp
authors.forename: Masaya
authors.initials: M
authors.lastname: Otsuka
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Okimoto
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Dohi
authors.forename: Shinji
authors.initials: S
authors.lastname: Mito
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Gomyo
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujii
authors.forename: Wataru
authors.initials: W
authors.lastname: Matsuura
authors.forename: Yukoh
authors.initials: Y
authors.lastname: Hirai
authors.forename: Nobuoki
authors.initials: N
authors.lastname: Kohno
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002423:Cause of Death; D003327:Coronary Disease / Q000150:complications / Q000401:mortality / Q000628:therapy; D023903:Coronary Restenosis / Q000517:prevention & control*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D000077583:Quinapril; D012307:Risk Factors; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; D000077583:Quinapril